Navigation Links
Iowa P.K. Press Punch

ProductsIowa P.K. Press Punch
Company Bausch & Lomb Storz
Item Iowa P.K. Press Punch
Features 
Description Designed for precise punching of the donor corneal button. Blade holder is designed for use with disposable trephine blades. Unique two color cutting block aids in centration of the donor tissue. Recessed base assures that the block is held centrally under the trephine blade. Supplied with two cutting blocks.
Info Bausch & Lomb Storz
Customer Service: (585) 338-6000
Web site: http://www.storz.com/

Related medicine products :

1. Press-on Prisms
2. Pressure Ridge Single Plate Molteno Implant (D1)
3. Pressure Ridge Double Plate Molteno Implant (DR2/DL2)
4. Thornton Press-On Ruler for Limbal Incisions
5. Ventrix™ NL950-100 Intercranial Pressure Monitoring System
6. Sophy Adjustable Pressure Valves
7. AcuMatch P-Series Press-Fit Femoral Stems
8. The Foundation 440 Series Press-Fit Stem
9. WaveMap™ & SmartWire™ Pressure System
10. Smartmap Pressure Instrument
11. Dual Pressure Sensor Intravascular Mikro-Tip Pressure Catheters; SPC-721
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...Mahajan underwent a minor surgery on Saturday as h... shot at by his brother//. Doctors at P.D. Hinduja...shed April 22 after Pravin Mahajan shot at him fro...Mahajan continued to be on a ventilator in the ICU...
...hat care home fees has increased by over 50 percen...oncurrent period basic state pension has risen by ...re home fees is bound to jump by another 25 percen...at many elderly people will not be able to cope wi...
...commended the use of breast cancer drug Herceptin ...review//. A license for the drug is to be issued i...alth and Clinical Excellence in the UK will decide...the NHS. The drug, which costs ?20,000 a year, is ...
...omplia which the European Medicines Agency (EMEA) ...oss//. After this its shares rose 2.7%. The U.S. ...ug for weight control. The chemical name of the dr... overweight or obese patients. But Sanofi failed t...
Other Medicine News:Health News:Pramod Mahajan Undergoes Third Surgery 2
(Date:9/3/2008)...URG, Md., Sept. 3 /- Panacea Pharmace... Patent Number 7,413,737 covering,antibodies again...HAAH), a,proprietary human cancer biomarker and th...in collaboration with the Massachusetts Institute ...ldwide rights to this patent,for development of hu...
(Date:9/3/2008)...o be Evaluated in Repeat-Dosing Study in Subjects ...irstCall/ -- Sangamo,BioSciences, Inc. (Nasdaq: S... clinical trial (SB-509-801) to evaluate its drug,...nerative motor-neuron disease for which there,are ... drug, SB-509, is an injectable formulation of a p...
(Date:9/2/2008)... September is Prostate Cancer Awareness Month, ...- September is,Prostate Cancer Awareness Month, an...nnounce a revolutionary new way to treat prostate ...of radiation. Prostate cancer is,the most common f...erKnife CEO, James G. Schwade, M.D., says, "for ma...
(Date:9/2/2008)...Call Scheduled for Today - Tuesday, September 2, 2... Time, MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire...q: ALXA ) today announced positive results from,i...o(R) loxapine) in,schizophrenic patients with acut...04 met the primary endpoint of the trial, which wa...
Breaking Medicine Technology:Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 2Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 3Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 4Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 5Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 6Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 7Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 8Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients 9Chiropractic Can Offer Relief from Stress Related Pain Health Problems 21650 1Chiropractic Can Offer Relief from Stress Related Pain Health Problems 21650 2Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 1Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 2Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 3Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 4Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 5Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 6Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 7Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 8Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 9Chindex International Inc Announces Fiscal 2008 Year End and Fourth Quarter Results 5950 10REM sleep associated with overweight in children and adolescents 21643 1REM sleep associated with overweight in children and adolescents 21643 2REM sleep associated with overweight in children and adolescents 21643 3Cell Therapeutics Inc Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 5947 1Cell Therapeutics Inc Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 5947 2